EUVIMEDEUVIMED entdecken
Crossref

Caffeine, chocolate, and adenosine antagonism in Parkinson’s disease

Heinz Reichmann

Ageing and Neurodegenerative Diseases · 2022

DOI: 10.20517/and.2022.24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ageing and Neurodegenerative Diseases, 2022. Verfasst von Heinz Reichmann. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is the second most common neurodegenerative disorder. It is generally accepted that dopamine replacement therapy substantially improves motor symptoms; however, there is a worldwide tendency to include nutrients in treatment strategies. In the present review, caffeine and chocolate are discussed. Caffeine use seems to postpone the occurrence of PD in men, and perhaps also in women who do not take postmenopausal hormone replacement therapy. There are contradictory data concerning possible caffeine-induced improvements in PD symptoms. Given that the basic action of caffeine is the antagonism of adenosine receptors, adenosine antagonists may be a new option for treating PD patients. Furthermore, PD patients tend to have increased chocolate consumption; this may be causally related to ingredients such as phenylethylamine. Thus, nutrients such as caffeine and chocolate may play an important role in postponing and/or improving symptoms in PD.

Zitieren

APA

Reichmann, H. (2022). Caffeine, chocolate, and adenosine antagonism in Parkinson’s disease. Ageing and Neurodegenerative Diseases. https://doi.org/10.20517/and.2022.24

Vancouver

Reichmann H. Caffeine, chocolate, and adenosine antagonism in Parkinson’s disease. Ageing and Neurodegenerative Diseases. 2022. doi:10.20517/and.2022.24

BibTeX
@article{Reichmann2022,
  author = {Reichmann, Heinz},
  title = {Caffeine, chocolate, and adenosine antagonism in Parkinson’s disease},
  journal = {Ageing and Neurodegenerative Diseases},
  year = {2022},
  doi = {10.20517/and.2022.24}
}
Kostenlos starten →